Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acalabrutinib and rituximab in elderly patients with untreated mantle cell lymphoma
2018-001850-80Phase 2Active
- Sponsor
- Skåne University Hospital
- Start
- Jan 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of acalabrutinib and rituximab in mantle cell lymphoma (MCL), sponsored by Skåne University Hospital. Primary endpoint: Progression-free survival. Started Jan 2021; status: active.
02
Drugs
acalabrutinibrituximab
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on 2018-001850-80.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001850-80.